TLRY

Over the past six months, Tilray Brands' stock price has been impacted by several key events. The stock declined by 62% over the last twelve months, despite generating $858 million in revenue. In April 2026, the stock experienced a parabolic surge following news that the U.S. Justice Department and FDA were reclassifying cannabis, but this rally faded. Tilray reported its Third Quarter Fiscal Year 2026 earnings on April 1, 2026, missing EPS estimates, and this earnings miss, coupled with an active equity shelf registration and insider selling, contributed to investor skepticism. Investor frustration has also been noted regarding the company's increasing focus on its beverage alcohol business.